Pharma
Attribution modelling: A practical guide for science and tech marketers
A guide to attribution modelling, how to select the right model for you, and what you need to know about marketing systems that are critical to helping you connect every marketing touchpoint to real ROI and make smarter, data-driven decisions. ...
How to prove the ROI of your content marketing in science and tech
Avoid another awkward boardroom moment where the marketing ROI question leaves you fumbling- this article shows you how to prove your content’s impact with clarity and confidence. ...
How to build a content strategy that works: A guide for science and tech marketers
It’s not enough to have great content for science and tech marketers - you need a strategy that aligns with your commercial goals and drives real ROI. So how do you build one? ...
RAREsummit25: CamRARE at 10 – Connecting Moments
2025 marks a special milestone — CamRARE’s 10th anniversary. A decade of progress. A future of possibilities. Over the past decade, we have championed collaboration, amplified patient voices, and driven progress in rare disease research, policy, and innovation. Through inspiring keynot...
Nuclera and Cytiva collaborate to accelerate characterization of proteins for drug development
Collaboration combines Nuclera’s eProtein Discovery System, which accelerates protein expression, purification and optimization, with Cytiva’s Biacore SPR system, which characterizes molecular interactionsCollaboration allows researchers to progress rapidly from DNA to purified and...
Cambridge AI Club for Biomedicine - June - New Methods in AI
The AI Club brings together the Biomedical AI and Machine Learning community in Cambridge, to discuss common themes and explore different topics and methodologies. Talks will be followed by pizza and networking. June Theme - New Methods in AISpeakers: ...
SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers
This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insig...
Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase 3 clinical trials in ...
Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinic...
Navigating tax: Essential strategies for R&D
With HMRC increasing its focus on tax governance, tax and finance teams face an increasing compliance burden, balancing value with risk management.When it comes to R&D tax relief processes, knowing what actions you need to take and when is challenging, especially against a backdrop ...